These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 24146095)

  • 1. Cancer-associated bone disease.
    Rizzoli R; Body JJ; Brandi ML; Cannata-Andia J; Chappard D; El Maghraoui A; Glüer CC; Kendler D; Napoli N; Papaioannou A; Pierroz DD; Rahme M; Van Poznak CH; de Villiers TJ; El Hajj Fuleihan G;
    Osteoporos Int; 2013 Dec; 24(12):2929-53. PubMed ID: 24146095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.
    Saylor PJ
    Asian J Androl; 2014; 16(3):341-7. PubMed ID: 24435057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of metastatic bone disease and treatment-induced osteoporosis in prostate cancer. Evolution of osteoprotective strategies].
    Todenhöfer T; Schwentner C; Schilling D; Gakis G; Stenzl A
    Urologe A; 2011 Sep; 50(9):1055-63. PubMed ID: 21744161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss.
    Dionísio MR; Mansinho A; Abreu C; Cavaco-Silva J; Casimiro S; Costa L
    Br J Clin Pharmacol; 2019 Jun; 85(6):1114-1124. PubMed ID: 30601585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
    Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
    Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
    Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "The use of bisphosphonates to treat skeletal complications in solid tumours".
    D'Oronzo S; Wood S; Brown JE
    Bone; 2021 Jun; 147():115907. PubMed ID: 33676057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bone effects of bisphosphonates and denosumab treatments in breast or prostate cancer].
    Biver E
    Rev Med Suisse; 2019 Apr; 15(647):824-830. PubMed ID: 30994985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal Health Part 1: Overview Of Bone Health and Management In the Cancer Setting.
    Turner B; Ali S; Drudge-Coates L; Pati J; Nargund V; Wells P
    Urol Nurs; 2016; 36(1):17-21, 26. PubMed ID: 27093759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
    Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
    J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
    Henk H; Teitelbaum A; Kaura S
    Curr Med Res Opin; 2012 Jul; 28(7):1119-27. PubMed ID: 22536885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
    Kudlacek S; Puntus T
    Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of bisphosphonates in breast and prostate cancers.
    Brown JE; Neville-Webbe H; Coleman RE
    Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
    Smith MR
    Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
    Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
    Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.